Table 1.
Baseline characteristics for the participants in the clinical trial.
| Characteristic | Fluoxetine + Placebo | Fluoxetine + Serine | P value |
|---|---|---|---|
| N | 20 | 20 | NA |
| Sex | F | F | NA |
| Age, years | 47.2 ± 5.3 | 48.4 ± 4.5 | 0.45 |
| BMI, kg/m2 | 27.2 ± 3.8 | 27.8 ± 4.9 | 0.67 |
| Weight change during the study (kg) | −0.54 ± 3.89 | 0.62 ± 4.12 | 0.37 |
| Menopausal status, n (%) | |||
| Postmenopausal | 12 (60%) | 13 (65%) | 1.00 |
| Late perimenopausal | 8 (40%) | 7 (35%) | 1.00 |
| Current calcium supplement user, n (%) | 5 (25%) | 4 (20%) | 1.00 |
| Current vitamin D supplement user, n (%) | 5 (25%) | 5 (25%) | 1.00 |
| Total lumbar spine BMD, g/cm2 | 0.94 ± 0.23 | 0.91 ± 0.17 | 0.64 |
| Total hip BMD, g/cm2 | 0.94 ± 0.17 | 0.99 ± 0.22 | 0.43 |
| Diagnosis | |||
| MDD | 20 | 20 | N/A |
| Montgomery–Åsberg depression rating scale | 28.6 ± 9.1 | 30.2 ± 7.8 | 0.55 |
| Use of other medications that may modify fracture risk | |||
| Proton-pump inhibitor, n (%) | 3 (15%) | 2 (10%) | 1.00 |
| Thiazolidinediones, n (%) | 1 (5%) | 1 (5%) | 1.00 |
Data were mean ± sem or the values with percentages. Student’s t-test, Mann–Whitney U test or Two-proportion z-test was used.